☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Eisai
Eisai’s Fycompa (perampanel) Injection Formulation Receives MHLW’s Marketing Authorization for Epilepsy
January 18, 2024
Eisai and Biogen’s Leqembi (Lecanemab) Receives the NMPA’s Approval for the Treatment of Alzheimer’s Disease
January 9, 2024
Eisai to Launch Leqembi (Lecanemab) in Japan for the Treatment of Alzheimer’s Disease (AD)
December 13, 2023
Eisai and BioArctic Presented Results of Leqembi as Subcutaneous Dosage Form in P-III Trial for Alzheimer’s Disease CTAD 2023
October 26, 2023
Michael Irizarry, SVP, Clinical Research, Eisai Shared Insights on P-III Results from Clarity AD Study
July 5, 2023
Eisai and Biogen Report the Health Canada Acceptance of New Drug Submission for Leqembi (lecanemab) to Treat Early Alzheimer's Dis...
May 16, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.